TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULINASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS

被引:16
作者
Gerety, Gregg [1 ]
Bebakar, Wan Mohamad Wan [2 ]
Chaykin, Louis [3 ]
Ozkaya, Mesut [4 ]
Macura, Stanislava [5 ]
Herslov, Malene Lundgren [5 ]
Behnke, Thomas [6 ,7 ]
机构
[1] Albany Med Coll, Div Community Endocrinol, 1365 Washington Ave,Suite 300, Albany, NY 12206 USA
[2] Hosp Univ Sains Malaysia, Kota Baharu, Malaysia
[3] Meridien Res, Bradenton, FL USA
[4] Gaziantep Univ, Sch Med, Dept Endocrinol, Sahinbey, Turkey
[5] Novo Nordisk AS, Vandtarnsvej Soborg, Denmark
[6] DKZN, Neuwied, Germany
[7] ZKSN, Neuwied, Germany
关键词
TYPE-2; ASPART; BASAL; HYPERGLYCEMIA; MANAGEMENT; GLARGINE; GLUCOSE; PEOPLE;
D O I
10.4158/EP15893.OR
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This 26-week, multicenter, randomized, open-label, parallel-group, treat-to-target trial in adults with type 2 diabetes compared the efficacy and safety of treatment intensification algorithms with twice-daily (BID) insulin degludec/insulin aspart (IDegAsp). Methods: Patients randomized 1: 1 to IDegAsp BID used either a 'Simple' algorithm (twice-weekly dose adjustments based on a single prebreakfast and preevening meal self-monitored plasma glucose [SMPG] measurement; IDegAsp[BIDSimple], n = 136) or a 'Stepwise' algorithm (once-weekly dose adjustments based on the lowest of 3 pre-breakfast and 3 pre-evening meal SMPG values; IDegAsp[BIDStep-wise], n = 136). Results: After 26 weeks, mean change from baseline in glycated hemoglobin (HbA1c) with IDegAsp[BIDSimple] was noninferior to IDegAsp[BIDStep-wise] (-15 mmol/mol versus-14 mmol/mol; 95% confidence interval [CI] upper limit, < 4 mmol/mol) (baseline HbA1c: 66.3 mmol/mol IDegAsp[BIDSimple] and 66.6 mmol/mol IDegAsp[BIDStep-wise]). The proportion of patients who achieved HbA1c < 7.0% (< 53 mmol/mol) at the end of the trial was 66.9% with IDegAsp[BIDSimple] and 62.5% with IDegAsp[BIDStep-wise]. Fasting plasma glucose levels were reduced with each titration algorithm (-1.51 mmol/L IDegAsp[BIDSimple] versus-1.95 mmol/L IDegAsp[BIDStep-wise]). Weight gain was 3.8 kg IDegAsp[BIDSimple] versus 2.6 kg IDegAsp[BIDStep-wise], and rates of overall confirmed hypoglycemia (5.16 episodes per patient-year of exposure [PYE] versus 8.93 PYE) and nocturnal confirmed hypoglycemia (0.78 PYE versus 1.33 PYE) were significantly lower with IDegAsp[BID(Stepwis)e] versus IDegAsp[BIDSimple]. There were no significant differences in insulin dose increments between groups. Conclusion: Treatment intensification with IDegAsp[BIDSimple] was noninferior to IDegAsp[BIDStepwise]. Both titration algorithms were well tolerated; however, the more conservative step-wise algorithm led to less weight gain and fewer hypoglycemic episodes. Clinicaltrials. gov: NCT01680341
引用
收藏
页码:546 / 554
页数:9
相关论文
共 17 条
[1]  
[Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004]
[2]   The replication of β cells in normal physiology, in disease and for therapy [J].
Butler, Peter C. ;
Meier, Juris J. ;
Butler, Alexandra E. ;
Bhushan, Anil .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (11) :758-768
[3]   Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial [J].
Dashora, U. K. ;
Sibal, L. ;
Ashwell, S. G. ;
Home, P. D. .
DIABETIC MEDICINE, 2007, 24 (04) :344-349
[4]   Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes [J].
Franek, E. ;
Haluzik, M. ;
Varzic, S. Canecki ;
Sargin, M. ;
Macura, S. ;
Zacho, J. ;
Christiansen, J. S. .
DIABETIC MEDICINE, 2016, 33 (04) :497-505
[5]  
Fulcher Gregory, 2014, J Med Econ, V17, P751, DOI 10.3111/13696998.2014.946992
[6]   Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient [J].
Garber, A. J. .
DIABETES OBESITY & METABOLISM, 2009, 11 :14-18
[7]   Premixed insulin treatment for type 2 diabetes: analogue or human? [J].
Garber, Alan J. ;
Ligthelm, Robert ;
Christiansen, Jens S. ;
Liebl, Andreas .
DIABETES OBESITY & METABOLISM, 2007, 9 (05) :630-639
[8]   Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus [J].
Heise, Tim ;
Nosek, Leszek ;
Roepstorff, Carsten ;
Chenji, Suresh ;
Klein, Oliver ;
Haahr, Hanne .
DIABETES THERAPY, 2014, 5 (01) :255-265
[9]   Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes [J].
Inzucchi, Silvio E. ;
Bergenstal, Richard M. ;
Buse, John B. ;
Diamant, Michaela ;
Ferrannini, Ele ;
Nauck, Michael ;
Peters, Anne L. ;
Tsapas, Apostolos ;
Wender, Richard ;
Matthews, David R. .
DIABETES CARE, 2015, 38 (01) :140-149
[10]   Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach [J].
Inzucchi, Silvio E. ;
Bergenstal, Richard M. ;
Buse, John B. ;
Diamant, Michaela ;
Ferrannini, Ele ;
Nauck, Michael ;
Peters, Anne L. ;
Tsapas, Apostolos ;
Wender, Richard ;
Matthews, David R. .
DIABETES CARE, 2012, 35 (06) :1364-1379